Previous studies identified different NRF2 inhibitors by directly or indirectly targeting NRF2 protein and/or the downstream proteins [24,25,26]; however, further assessment of the specific NRF2 pathway inhibition in tumor cells could help us to identify or develop a useful therapeutic approach to KLK LUAD. This evidence concerns the gene NFE2L2 and neoplasm.